Of the campaignfinance world which many people in this town care about very intensely and other people in the country dont. Other than they see headlines and president obama at the state of the union criticizing the Supreme Court. They got that buzz, but i dont think many people understood it. Lay a candor, i will marker around this discussion. I wont try to get into the discussion. 441 b the parties debate that. Lets talk about the court and how they look a Campaign Finance and what this may mean in terms of how they approach some of these cases. The commentary on the case some of them is trying to tear it up as a citizens united. A bedrock campaignfinance decision from the 1970s may be in some danger based on the march of cases waste on the past few cycles where the court has been First Amendment protected and been willing to strike down campaignfinance or strictures. Today have cases been on the expenditure side. This is a contribution limit case in what is going on is Sean Mccutche
Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) Director Daniel K. Spiegelman sold 3,788 shares of Myriad Genetics stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $22.04, for a total transaction of $83,487.52. Following the sale, the director now directly owns 36,705 shares in the company, […]
Artisan Partners Limited Partnership trimmed its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,433,377 shares of the company’s stock after selling 103,770 shares during the quarter. […]
Myriad Genetics (NASDAQ:MYGN – Free Report) had its target price increased by Piper Sandler from $23.00 to $28.00 in a research note issued to investors on Monday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock. Several other equities research analysts have also issued reports on MYGN. Leerink Partnrs upgraded shares […]
Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) CEO Paul J. Diaz sold 57,844 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $25.13, for a total transaction of $1,453,619.72. Following the transaction, the chief executive officer now directly owns 1,236,166 shares of […]